JonathanMarkDucoreMD

PubMed

• Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
  Mary Mathias, Aby Abraham, Mark J Belletrutti, Manuel Carcao, Manuela Carvalho, Hervé Chambost, Anthony K C Chan, Leonid Dubey, Jonathan Ducore, Michael Gattens, Paolo...> ;European Journal of Haematology. 2023 Oct 1
• Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untrea...
  Mary Mathias, Marina Abashidze, Aby Abraham, Mark J Belletrutti, Manuel Carcao, Hervé Chambost, Anthony K C Chan, Leonid Dubey, Jonathan Ducore, Thierry Lambert, Natal...> ;Haemophilia. 2023 Jul 1
• Medical imaging utilization and associated radiation exposure in children with down syndrome.
  Emily C Marlow, Jonathan M Ducore, Marilyn L Kwan, Erin J A Bowles, Robert T Greenlee, Jason D Pole, Alanna K Rahm, Natasha K Stout, Sheila Weinmann, Rebecca Smith-Bin...> ;Plos One. 2023 Jan 1
• 5 citations
  Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
  Steven W Pipe, Cédric Hermans, Meera Chitlur, Manuel Carcao, Giancarlo Castaman, Joanna A Davis, Jonathan Ducore, Amy L Dunn, Miguel Escobar, Janna Journeycake, Osman ...> ;Haemophilia. 2022 Jul 1
• 6 citations
  The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
  Miguel A. Escobar, Giancarlo Castaman, Santiago Bonanad Boix, Michael U. Callaghan, Philippe de Moerloose, Jonathan M. Ducore, Cédric Hermans, Janna M. Journeycake, Ci...> ;Haemophilia. 2021 Oct 11
• 5 citations
  PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A...
  Miguel A. Escobar, James V. Luck, Yevhenii Averianov, Jonathan M. Ducore, Maria Fernanda Lopez Fernandez, Adam Giermasz, Daniel P. Hart, Janna M. Journeycake, Craig M....> ;Haemophilia. 2021 Oct 6
• 4 citations
  Safety and efficacy of BAY 94–9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A
  Elena Santagostino, Shadan Lalezari, Mark T. Reding, Jonathan M. Ducore, Heng Joo Ng, Lone Hvitfeldt Poulsen, Lisa A. Michaels, Camila Linardi> ;Haemophilia. 2021 May 3
• 18 citations
  Leukemia Risk in a Cohort of 3.9 Million Children With and Without Down Syndrome.
  Emily C. Marlow, Jonathan M. Ducore, Marilyn L. Kwan, Stephanie Y. Cheng, Erin J. Aiello Bowles, Robert T. Greenlee, Jason D. Pole, Alanna Kulchak Rahm, Natasha K. Sto...> ;The Journal of Pediatrics. 2021 Jul 1
• 2 citations
  Assessing Safe Discharge Criteria for Pediatric Oncology Patients Admitted for Febrile Neutropenia.
  Emily Huschart, Jonathan M. Ducore, Jong Chung> ;Journal of Pediatric Hematology/oncology. 2021 Aug 1
• 14 citations
  Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study
  Ri Liesner, Aby Abraham, Carmen Altisent, Mark Belletrutti, Manuel Carcao, Manuela Carvalho, Hervé Chambost, Anthony K.C. Chan, Leonid Dubey, Jonathan M. Ducore, Micha...> ;Thrombosis and Haemostasis. 2021 Feb 13
• 2 citations
  Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres.
  Jeffrey S. Stonebraker, Jonathan M. Ducore> ;Haemophilia. 2021 Jan 1
• 20 citations
  Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.
  Elena Santagostino, Shadan Lalezari, Mark T. Reding, Jonathan M. Ducore, Heng Joo Ng, Lone Hvitfeldt Poulsen, Lisa A. Michaels, Camila Linardi> ;Thrombosis Research. 2019 Nov 1
• 1 citations
  A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor.
  Courtney D. Thornburg, Jonathan M. Ducore> ;Haemophilia. 2019 Jan 1
• 25 citations
  Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study
  R. Liesner, M. Abashidze, Olga Aleinikova, Carmen Altisent, Mark Belletrutti, A. Borel-Derlon, Manuel Carcao, Hervé Chambost, Anthony K.C. Chan, Leonid Dubey, Jonathan...> ;Haemophilia. 2018 Mar 1
• 437 citations
  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
  Lindsey A. George, Spencer K. Sullivan, Adam Giermasz, John E.J. Rasko, Benjamin J. Samelson-Jones, Jonathan M. Ducore, Adam Cuker, Lisa M. Sullivan, Suvankar Majumdar...> ;The New England Journal of Medicine. 2017 Dec 6
• 20 citations
  PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
  Michael Wang, J. B. Lawrence, Doris Quon, Jonathan M. Ducore, Mindy L. Simpson, Lisa N. Boggio, Ian S. Mitchell, G. Yuan, W. A. Alexander, J.-F. Schved> ;Haemophilia. 2017 Nov 1
• 15 citations
  Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors
  Jonathan M. Ducore, J. B. Lawrence, Mindy L. Simpson, Lisa N. Boggio, A. Bellon, Jacobus Burggraaf, Jasper Stevens, Matthijs Moerland, J. Frieling, Joannes A. A. Reije...> ;Haemophilia. 2017 Nov 1
• 8 citations
  Primary Renal Lymphoma Presenting as End-Stage Renal Disease.
  Lavjay Butani, Jonathan M. Ducore> ;Case Reports in Medicine. 2017 Oct 2
• 1 citations
  End-Stage Renal Disease From Cast Nephropathy in a Teenager With Neuroendocrine Carcinoma.
  Lavjay Butani, Jonathan M. Ducore> ;Journal of Pediatric Hematology/oncology. 2016 Jul 1
• 26 citations
  Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery
  Tyler W. Buckner, Andrew D. Leavitt, Margaret V. Ragni, Christine L. Kempton, M. Elaine Eyster, Adam Cuker, Steven R. Lentz, Jonathan M. Ducore, Cindy A. Leissinger, M...> ;Thrombosis and Haemostasis. 2016 Mar 24
• 5 citations
  Dust metal loadings and the risk of childhood acute lymphoblastic leukemia
  Todd P. Whitehead, Mary H. Ward, Joanne S. Colt, Gary V. Dahl, Jonathan M. Ducore, Kyndaron Reinier, Robert B. Gunier, S. Katharine Hammond, Stephen M. Rappaport, Cath...> ;Journal of Exposure Science &amp; Environmental Epidemiology. 2015 Mar 4
• 13 citations
  Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.
  Jonathan M. Ducore, Maricel G. Miguelino, Jerry S. Powell> ;Expert Review of Hematology. 2014 Sep 12
• 4 citations
  WARM N COLD: malignant and benign renal tumors in children
  Thomas Ray Sanchez, Jonathan M. Ducore, Jay Balagtas, Christopher Molloy, Sandra L. Wootton-Gorges> ;Emergency Radiology. 2014 Feb 26
• 4 citations
  Children and adolescents with ALL are taller than expected at diagnosis.
  Tannie Huang, Jonathan M. Ducore> ;Journal of Pediatric Hematology/oncology. 2014 Jan 1
• 55 citations
  Tobacco Smoke Exposure and the Risk of Childhood Acute Lymphoblastic and Myeloid Leukemias by Cytogenetic Subtype
  Catherine Metayer, Luoping Zhang, Joseph L. Wiemels, Karen Bartley, Joshua D. Schiffman, Xiaomei Ma, Melinda C. Aldrich, Jeffrey S. Chang, Steve Selvin, Cecilia Fu, Jo...> ;Cancer Epidemiology, Biomarkers &amp; Prevention. 2013 Jul 12
• Join now to see all

Abstracts/Posters

• Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year
  Jonathan M. Ducore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019